During the study, participants will receive bevacizumab infusions over a period of time. Researchers will monitor the immune system changes in these patients to understand how the treatment might affect the progression of the disease. The study will also look at how long patients remain free from local relapse, how long the disease does not worsen, and overall survival rates.

Additionally, the study will explore certain components in the blood, such as extracellular vesicles, which are tiny particles released by cells, and their content, including micro-RNA and protein, as well as free DNA-RNA fragments. This research aims to provide insights into the biological changes occurring in patients with glioblastoma multiforme during treatment with bevacizumab.

The treatment involves hematopoietic stem cells (blood-forming cells) that are collected from the patient’s own body. These cells are modified in a laboratory to include a gene that produces interferon alpha-2, a substance that can help fight cancer. The modified cells are then given back to the patient through an intravenous infusion (through a vein).

The main purpose of this follow-up study is to monitor the long-term safety of Temferon treatment. The study will specifically look at whether the modified cells could potentially cause any blood disorders or other health issues over time. Patients who have previously received Temferon treatment will be monitored for several years to ensure their safety and to track how well the treatment continues to work.

The purpose of this research is to evaluate how well Berubicin works compared to Lomustine in extending survival time for patients whose brain tumor has come back after their first treatment. During the study, patients will receive either Berubicin through an infusion into their veins or Lomustine taken by mouth. The study is open-label, which means both doctors and patients will know which treatment is being given.

The study will track several important measurements including how long patients survive, how long it takes for the tumor to grow, and whether the tumor shrinks in response to treatment. Doctors will use MRI scans to monitor changes in the tumor throughout the study. The effectiveness of the treatment will be determined by comparing survival times between patients receiving Berubicin and those receiving Lomustine.

The purpose of the study is to evaluate how effective this new treatment is in helping patients with glioblastoma live longer without their disease getting worse. Participants in the study will receive the treatment as an injection under the skin, known as an intradermal injection. The study will compare the effects of this treatment with those of standard therapy, which typically includes a combination of radiation and chemotherapy. Some participants may receive a placebo instead of the new treatment to help researchers understand its true effects.

Throughout the study, participants will undergo regular assessments, including MRI scans, to monitor the size and progression of their tumors. These assessments will help determine how well the treatment is working. The study aims to provide valuable information on whether this new immune therapy can improve outcomes for patients with glioblastoma.

The purpose of the study is to assess the safety and anti-tumor activity of these treatments when used together. After the tumor is surgically removed, patients will receive an injection of ipilimumab directly into the tumor site, along with nivolumab. Following this, nivolumab will be administered both into the cavity left by the tumor and through the vein. The study will monitor how the body responds to these treatments and any side effects that may occur.

Participants in the study will undergo regular check-ups and tests to track their progress. The study aims to gather information on how well these treatments work together in fighting glioblastoma and to ensure they are safe for patients. The trial will continue until the end of 2026, with the goal of improving treatment options for those affected by this aggressive form of brain cancer.

The purpose of the study is to explore how these changes in the brain’s metabolism can be detected using this advanced MRI technique. Participants in the study will receive the hyperpolarized pyruvate injection, and then undergo MRI scans to observe how the substance moves through the brain and how it is converted into other compounds. This will help researchers understand more about the tumor’s behavior and the effects of treatment.

The study will follow participants over a period of time to monitor the progression of the disease and the overall survival of the patients. By using this innovative imaging method, the study aims to provide new insights into the treatment of glioblastoma and potentially improve outcomes for patients with this challenging condition.

Participants in the study will be randomly assigned to receive either the early treatment with temozolomide or the standard treatment protocol. The study will begin treatment within 15 days after surgery or biopsy, which is earlier than the usual start time. The treatment will continue for a maximum period of 10 months. Throughout the study, participants will be monitored for their overall health and any side effects they may experience. The study aims to understand if the early use of temozolomide can lead to better outcomes for patients with glioblastoma.

Overall survival, which is the time from the start of the study until death from any cause, will be the main focus of the study. Additionally, the study will look at other factors such as the time until the disease progresses and the quality of life without symptoms or side effects. The study will also collect information on any adverse events, which are unwanted effects that may occur during the treatment. This information will help researchers understand the potential benefits and risks of starting temozolomide treatment earlier in patients with glioblastoma.

The purpose of the study is to determine if adding LSTA1 to the standard treatment can improve survival rates for patients with GBM. Participants in the study will be randomly assigned to receive either the combination of LSTA1 and Temozolomide or Temozolomide with a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased and reliable.

Throughout the study, participants will undergo regular check-ups and tests, including MRIs, to monitor their health and the progress of the treatment. The study will last for a period of time, and researchers will collect data on overall survival and other health outcomes. The goal is to find out if LSTA1 can provide a significant benefit to patients with GBM when used alongside the current standard of care.

Participants in the study will undergo a process where their tumor cells are tested with various drugs to find the most effective treatment for their specific cancer. This approach is known as an Individualized Systems Medicine strategy. The study aims to determine if this method can successfully identify a treatment plan tailored to each patient’s unique cancer profile. The trial will also monitor the size of the tumor, any side effects from the treatments, and the overall survival of the patients involved.

The study will take place over a period of time, with the goal of completing by early 2026. During the trial, researchers will assess the ability to perform drug screenings and select possible treatment strategies based on the results. This innovative approach hopes to improve outcomes for patients with recurrent glioblastoma by providing more personalized and effective treatment options.

The purpose of the study is to evaluate whether adding Valganciclovir to the usual treatment can help patients live longer. Participants in the study will be randomly assigned to receive either Valganciclovir or a placebo, which looks like the Valganciclovir tablet but does not contain the active ingredient. The study will follow patients over a period of time to monitor their health and any side effects they may experience.

Throughout the study, patients will continue to receive their standard treatment, which typically includes radiation therapy and a chemotherapy drug called temozolomide. The trial aims to provide valuable information on whether Valganciclovir can be a beneficial addition to the current treatment options for glioblastoma patients.